Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

PDX_RNAseq

ABSTRACT: PDX_RNAseq

TISSUE(S): ['lymphoma']

DISEASE(S): ['lymphoma']

SUBMITTER: Ying Fang

PROVIDER: OEX00013640 | NODE | 2021-06-11

REPOSITORIES: NODE

ACCESS DATA

Json Xml

Similar Datasets

L1000 Dataset -small molecule, CRISPR perturbagens- LINCS Phase 2 (December 2015)

Project description:Transcriptional profiles of multiple cell and perturbation types: 23 cells are treated with 311 chemical perturbagens and CRISPR reagents. The expression level for 978 representative genes is measured.

2015-12-31 | LDS-1293 | LINCS

L1000 Dataset -small molecule perturbagens- LINCS Joint Project

Project description:Transcriptional profiles of cultured human breast cancer cell lines treated with small molecules: 5 cell lines are treated with 109 small molecules and the expression of 978 representative genes is measured, as a part of the LINCS Joint Project.

2014-05-30 | LDS-1203 | LINCS

iPSC (Exp 1) - ALS, SMA and Control (unaffected) subject-derived iPSC lines - RNA-seq

Project description:RNA-Seq was carried out on isolated mRNA obtained from induced Pluripotnent Stem Cells (iPSC) cell lines. These lines were derived from ALS, SMA and Control (unaffected) individuals (three of each).

2016-09-01 | LDS-1356 | LINCS

L1000 Dataset -small molecule perturbagens- LINCS Phase 2 (June 2015)

Project description:Transcriptional profiles of multiple cells treated with small molecule perturbagens: The expression level is measured for 978 representative genes in 15 cell lines treated with 241 small molecules.

2015-06-30 | LDS-1233 | LINCS

L1000 Dataset -small molecule perturbagens- LINCS Phase 1

Project description:Transcriptional profiles of cultured human cancer cell lines treated with small molecules: Expression of 978 representative genes is measured in 39 cell lines perturbed by 13 thousands of small molecules.

2014-05-30 | LDS-1191 | LINCS

iMN (Exp 2) - ALS, SMA and Control (unaffected) iMN cell lines differentiated from iPS cell lines using a long differentiation protocol - RNA-seq

Project description:Total RNA-Seq was carried out on rRNA depleted RNA obtained from motor neuron lines generated from subject induced pluripotent stem cell (iPSC) lines. The iPSC lines were derived from 4 ALS, 3 SMA and 3 Control (unaffected) individuals, in duplicate.

2017-05-01 | LDS-1398 | LINCS

diMN (Exp 3) - ALS and Control (unaffected) diMN cell lines differentiated from iPS cell lines using a short and direct differeintiation protocol - RNA-seq

Project description:Total RNA-Seq was carried out on rRNA depleted RNA obtained from motor neuron lines generated from subject induced pluripotent stem cell (iPSC) lines. The iPSC lines were derived from 11 ALS and 4 Control (unaffected) individuals, in duplicate.

2017-10-13 | LDS-1499 | LINCS

Tyrosine Kinase Inhibitor-induced cardiotoxicity in hiPSC derived cardiomyocytes - pilot dataset

Project description: Not available

2018-03-20 | LDS-1516 | LINCS

3'-DGE mRNA-sequencing transcriptomic dataset for 914 primary human cardiomyocyte cell samples

Project description:Each of 914 cell samples either at the control condition or treated with FDA-approved cancer drugs is sequenced by the single-ended 3'-DGE mRNA-sequencing method with a read length of 46 base pairs, and a total of 914 raw sequence data files in the FASTQ format are generated. These sequence data files are then analyzed by a high-performance computational pipeline and ranked lists of gene signatures and biological processes related to drug-induced cardiotoxicity are generated for each drug. The raw sequence datasets and the analysis results have been carefully controlled for data quality, and they are made publicly available at the Gene Expression Omnibus (GEO) database repository of NIH. As such, this broad drug-stimulated transcriptomi dataset is valuable for the prediction of drug toxicities and their mitigations.

2020-11-09 | LDS-1592 | LINCS

L1000 MCF10A Deep Dive Dataset: treatment with ligands

Project description: Not available

2021-01-20 | LDS-1603 | LINCS